Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.

Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, et al.